Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: A subgroup analysis of the RE-LY trial

European Journal of Heart Failure

Volumn 15, Issue 9, 2013, Pages 1053-1061

  Ferreira, Jorge ^a   Ezekowitz, Michael D ^b   Connolly, Stuart J ^c   Brueckmann, Martina ^d,e   Fraessdorf, Mandy ^d   Reilly, Paul A ^f   Yusuf, Salim ^c   Wallentin, Lars ^g  

^a HOSPITAL DE SANTA CRUZ   (Portugal)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^g UPPSALA UNIVERSITY   (Sweden)

Author keywords

Anticoagulation; Atrial fibrillation; Dabigatran etexilate; Heart failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DABIGATRAN ETEXILATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; DIURETIC THERAPY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; EMBOLISM; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PRIORITY JOURNAL;

ANTICOAGULATION; ATRIAL FIBRILLATION; DABIGATRAN ETEXILATE; HEART FAILURE;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; RISK FACTORS; STROKE; WARFARIN;

EID: 84883171753     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1093/eurjhf/hft111     Document Type: Article

References (31)

1. Cleland JG, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J 2001;22:623-626. (Pubitemid 32622421)
2. Nieuwlaat R, Eurlings LW, Cleland JG, Cobbe SM, Vardas PE, Capucci A, López-Sendòn JL, Meeder JG, Pinto YM, Crijns HJ. Atrial fibrillation and heart failure in cardiology practice: reciprocal impact and combined management from the perspective of atrial fibrillation: results of the Euro Heart Survey on atrial fibrillation. J Am Coll Cardiol 2009;53:1690-1698.
3. Maisel WH, Stevenson LW. Atrial fibrillation in heart failure: epidemiology, patho-physiology, and rationale for therapy. Am J Cardiol 2003;91(Suppl):2D-8D. (Pubitemid 36369329)
4. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillationisassociated withanincreased risk for mortality and heartfailure progres-sioninpatients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998;32:695-703. (Pubitemid 28435256)
5. Stroke in AF working group. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. Neurology 2007;69:546-554.
6. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohnloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibril-lationofthe European Societyof Cardiology (ESC). Eur Heart J 2010;31:2369-2429.
7. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Eur Heart J 2012;33:2719-2747.
8. Witt DM, Delate T, Clark NP, Martell C, Tran T, Crowther MA, Garcia DA, Ageno W, Hylek EM; Warped Consortium. Twelve-month outcomes and predictors of very stable INR control in prevalent warfarin users. J Thromb Haemost 2010;8:744-749.
9. Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol 2011;57:173-180.
10. DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M; AFFIRM Investigators. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2005;149:650-656.
11. Cleland JG, Shelton R, Nikitin N, Ford S, Frison L, Grind M. Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials. Eur J Heart Fail 2007;9:730-739. (Pubitemid 46702817)
12. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, WallentinL; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrialfibrillation.NEngl J Med 2009;361:1139-1151.
13. Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. Newly identified events in the RE-LY trial. N Engl J Med 2010;363:1875-1876.
14. Ezekowitz MD, Connolly SJ, Parekh A, Reilly PA, Varrone J, Wang S, Oldgren J, Themeles E, Wallentin L, Yusuf S. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran. Am Heart J 2009;157:805-810.
15. Diener HC, Connolly SJ, Ezekowitz MD, Wallentin L, Reilly PR, Yang S, Xavier D, Di Pasquale G, Yusuf S, for the RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157-1163.
16. Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, Pais P, Dans A, Eikelboom J, Oldgren J, Pogue J, Reilly PA, Yang S, Connolly SJ, on behalf ofthe RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 2010;376:975-983.
17. Eikelboom JW, Wallentin L, Connolly SJ, Ezekowitz M, Healey JS, Oldgren J, Yang S, Alings M, Kaatz S, Hohnloser SH, Diener HC, Franzosi MG, Huber K, Reilly P, Varrone J, Yusuf S. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial. Circulation 2011;123:2363-2372.
18. Oldgren J, Alings M, Darius H, Diener HC, Eikelboom J, Ezekowitz MD, Kamensky G, Reilly PA, Yang S, Yusuf S, Wallentin L, Connolly SJ, on behalf of the RE-LY Investi-gators.Risks for stroke, bleeding, and deathinpatients with atrialfibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med 2012;155:660-668.
19. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870. (Pubitemid 32537350)
20. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on atrial fibrillation. Chest 2010; 137:263-272.
21. Mulder BA, Kamphuisen PW, Van Gelder IC. Stroke aetiology in heart failure: towards patient-tailored prevention of stroke. Eur J Heart Fail 2012;14:230-231.
22. Ogilvie IM, Newton N, Welner SA, Cowell W, Lip GY. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am J Med 2010;123:638-645.
23. Ahmad Y, Lip GY, Apostolakis S. New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation. Expert Rev Cardiovasc Ther 2012;10:1471-1480.
24. Choudry NK, Anderson GM, Laupacis A, Ross-Degnan D, Normand SL, Soumerai SB. Impact of adverse events on prescribing warfarin in patients with atrial fibrillation: matched pair analysis. BMJ 2006;332:141-145.
25. Ferrari GM, Klersy C, Ferrero P, Fantoni C, Salerno-Uriarte D, Manca L, Devecchi P, Molon G, Revera M, Curnis A, Braga SS, Accardi F, Salerno-Uriarte JA, for the ALPHA Study Group. Atrial fibrillation in heart failure patients: prevalence in daily clinical practice and effect on the severity of symptoms. Data from the ALPHA study registry. Eur J Heart Fail 2007;9:502-509. (Pubitemid 46561482)
26. Bourlag BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysi-ology, diagnosis, and treatment. Eur Heart J 2011;32:670-679.
27. Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, Fauchier L. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur J Heart Fail 2012;14:295-301.
28. Huisman MV, Lip GYH, Diener HC, Brueckmann M, van Ryn J, Clemens A. Dabiga-tran etexilate for stroke prevention inpatients with atrialfibrillation: resolving uncertainties in routine practice. Thromb Haemost 2012;107:838-847.
29. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009; 53;557-573.
30. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003;108:977-982. (Pubitemid 37048228)
31. Yusuf S, Garg R. Design, results and interpretation of randomized, controlled trials in congestive heart failure and left ventricular dysfunction. Circulation 1993;87 (Suppl. VII):115-121.